Top Markets
#1 MowCat MowCat +26.51%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +17.74%
#3 Versatize Coin Versatize Coin +16.66%
#4 QuantixAI QuantixAI +14.43%
#5 Pons Pons +13.72%
#6 OriginTrail OriginTrail +13.50%
#7 Wrapped NXM Wrapped NXM +10.25%
#8 Collector Crypt Collector Crypt +8.37%
#9 Siren Siren +8.14%
#10 DAPPOS DAPPOS +7.09%
Coin of the day
MowCat MowCat
Innstillinger
Språk
NORSK
Valuta
USD
Tema
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOP
Rangering i aksjer #20771
ZIOPHARM Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to... ZIOPHARM Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing innovative immuno-oncology treatments for cancer patients. The company leverages its proprietary Sleeping Beauty platform, which employs non-viral genetic engineering to modify T-cells outside the body using a transposon/transposase system for subsequent infusion. Additionally, ZIOPHARM is advancing its Controlled IL-12 technology, designed to precisely regulate the expression of interleukin-12 (IL-12), a key immune system regulator, to direct the patient's immune response against cancer cells. Its pipeline features several promising therapeutic candidates, including T-cell receptor (TCR) plus T-cell therapies aimed at solid tumors, chimeric antigen receptor (CAR) T-cell therapies specifically targeting CD19 for hematologic malignancies, and Ad-RTS-hIL-12 combined with veledimex, a gene delivery system for controlled IL-12 production under investigation for treating recurrent adult glioblastoma multiforme. ZIOPHARM maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., and research and development agreements, alongside patent licensing, with institutions such as The University of Texas MD Anderson Cancer Center and the National Cancer Institute. The company's headquarters are located in Boston, Massachusetts.
Aksjekurs
$0.8657
Sist synkronisert: 2022-01-26
Markedsverdi
$122.22M
Endring (1 dag)
-0.88%
Endring (1 år)
0.00%
Land
US
Handel ZIOPHARM Oncology, Inc. (ZIOP)

Kategori

Healthcare
P/E-forhold for ZIOPHARM Oncology, Inc. (ZIOP)
P/E-forhold per 2026 TTM: 0
Ifølge ZIOPHARM Oncology, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for ZIOPHARM Oncology, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.